Financial Performance - Total revenues for Q3 2025 were $179.5 million, up 6% from $168.6 million in Q3 2024[5] - Net product sales for EXPAREL were $139.9 million, reflecting a 9% volume growth compared to $132.0 million in Q3 2024[5] - Non-GAAP net income was $31.8 million, or $0.72 per share (basic), compared to $38.2 million, or $0.83 per share (basic) in Q3 2024[12] - Adjusted EBITDA for Q3 2025 was $49.4 million, down from $54.7 million in Q3 2024[12] - The company reported a net income of $5.43 million in Q3 2025, a significant recovery from a net loss of $143.47 million in Q3 2024[46] - Non-GAAP net income for Q3 2025 was $31.84 million, compared to $38.16 million in Q3 2024, indicating a decrease of 16.5%[46] - Total revenues for the nine months ended September 30, 2025, were $529.54 million, up from $513.71 million in the same period of 2024, marking a 3.1% increase[44] - For the three months ended September 30, 2025, total revenues were $179.5 million, compared to $168.6 million for the same period in 2024, representing a year-over-year increase of approximately 5.5%[68] Expenses and Costs - Research and development expenses increased to $26.0 million in Q3 2025 from $19.1 million in Q3 2024[12] - Selling, general and administrative expenses rose to $91.8 million in Q3 2025, compared to $74.3 million in Q3 2024[12] - Research and development expenses increased to $25.97 million in Q3 2025, compared to $19.10 million in Q3 2024, reflecting a 36.4% rise[44] - Research and development expenses for the nine months ended September 30, 2025, were $79.9 million, compared to $57.7 million for the same period in 2024, reflecting an increase of approximately 38.5%[68] - The company recognized $7.00 million in legal settlement costs related to patent infringement suits during the nine months ended September 30, 2025[52] - The company incurred $3.7 million in employee termination benefit charges in Q3 2025 as part of a workforce reduction due to improved manufacturing efficiencies[48] - Acquisition-related expenses in Q3 2025 primarily involved costs associated with the acquisition of GQ Bio[51] - The GAAP cost of goods sold for the three months ended September 30, 2025, was $34.3 million, down from $38.9 million in the same period of 2024[68] Guidance and Projections - The company updated its full-year 2025 revenue guidance to a range of $725 million to $735 million, down from the previous range of $730 million to $750 million[13] - Non-GAAP gross margin guidance was increased to 80% to 82%, up from the previous range of 78% to 80%[13] - The company expects total revenues for the full year 2025 to be in the range of $725 million to $735 million, with a gross margin projected between 80% to 82%[74] Assets and Liabilities - Total current assets decreased from $745,130,000 in December 2024 to $562,751,000 in September 2025, a decline of approximately 24.5%[42] - Cash and cash equivalents dropped significantly from $276,774,000 in December 2024 to $147,589,000 in September 2025, representing a decrease of about 46.3%[42] - Inventories increased from $125,282,000 in December 2024 to $157,680,000 in September 2025, an increase of approximately 25.8%[42] - Total liabilities decreased from $774,168,000 in December 2024 to $522,938,000 in September 2025, a reduction of about 32.4%[42] - Long-term debt remained relatively stable, decreasing slightly from $383,545,000 in December 2024 to $376,721,000 in September 2025[42] - The total stockholders' equity decreased from $778,348,000 in December 2024 to $727,214,000 in September 2025, a decline of approximately 6.6%[42] Product Development and Research - The company reported promising Phase 1 study results for PCRX-201, showing sustained improvements in knee pain, stiffness, and function over two years[34] - The HCAd vector platform acquired in February 2025 is expected to enable the production of thousands of doses in a single batch, enhancing cost efficiency[37] - The company is currently conducting a Phase 2 study (ASCEND study) for PCRX-201, indicating ongoing commitment to product development[35] - EXPAREL sales amounted to $139.90 million in Q3 2025, up from $132.00 million in Q3 2024, representing a 5.4% growth[44] Shareholder Actions - The company repurchased 2.0 million shares at an average price of $25.30 per share, totaling $50.0 million[10]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 47.7 million units at C$0.42 per unit, aiming to raise C$20.0 million due to strong investor demand [1][3] Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2] - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3] - An over-allotment option allows underwriters to purchase an additional 15% of the units sold to cover over-allotments [4] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Group 3: Company Overview - PharmaCorp is focused on acquiring and operating community pharmacies in Canada, empowering pharmacists as equity partners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies [8]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 35.7 million units at a price of C$0.42 per unit, aiming to raise gross proceeds of C$15.0 million for future acquisitions and working capital [1][3]. Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2]. - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3]. - The underwriters have an over-allotment option to purchase an additional 15% of the units sold to cover over-allotments and for market stabilization [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards future acquisition opportunities and general working capital requirements [3]. Group 3: Company Overview - PharmaCorp is a Canadian pharmacy acquisition platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [7]. - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies across Canada [8].

Core Insights - Pacira BioSciences has completed patient enrollment in Part A of its Phase 2 ASCEND study for PCRX-201, a novel gene therapy for knee osteoarthritis, with topline results expected by the end of 2026 [1][6][10] Study Overview - The ASCEND study is a two-part, multicenter trial involving approximately 135 patients aged 45 to 80 with painful knee osteoarthritis at Kellgren-Lawrence Grades 2, 3, or 4 [4] - Part A randomizes about 45 patients to evaluate two doses of PCRX-201, with a 1:1:1 randomization to Dose A, Dose B, or saline, all receiving corticosteroid pretreatment [5][6] - The primary endpoint includes treatment-emergent adverse events and secondary endpoints assess pain and physical function changes at Weeks 38 and 52 [7] Product Details - PCRX-201 is designed to enhance IL-1Ra production locally in the knee joint, targeting chronic inflammation and pain associated with osteoarthritis [2][9] - The therapy utilizes a high-capacity adenovirus vector platform, allowing for efficient gene delivery and the potential for redosing [12][17] - The product has received RMAT designation from the FDA and ATMP designation from the EMA, highlighting its clinical promise [11] Company Background - Pacira BioSciences focuses on innovative, non-opioid pain therapies, with existing products including EXPAREL, ZILRETTA, and iovera° [15] - The company aims to address prevalent diseases like osteoarthritis through advanced gene therapy solutions [15]

Core Insights - Pacira BioSciences has announced an exclusive worldwide license and collaboration agreement with AmacaThera for the development of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine aimed at postsurgical pain control [1][2] Company Strategy - The addition of AMT-143 to the pipeline aligns with Pacira's 5x30 growth strategy, focusing on clinical stage, derisked opportunities that complement existing pain management offerings [2] - The company aims to enhance its leadership in opioid-sparing pain management through this new asset, which is expected to improve patient outcomes and expand treatment options [2] Financial Terms of the Agreement - Under the agreement, Pacira will fund the clinical development up to commercial launch, with AmacaThera receiving an upfront payment of $5 million, along with potential future milestone payments and a tiered royalty on net sales [3] Product Details - AMT-143 is designed for postsurgical pain control and demonstrated sustained release of ropivacaine for up to 14 days in a Phase 1 study [4] - The product utilizes AmacaThera's hydrogel-based drug delivery platform, which allows for slow release while minimizing systemic side effects [5] Current Product Portfolio - Pacira currently offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, which target various pain management needs [6]

Core Insights - Pacira BioSciences, Inc. will report its third quarter financial results on November 6, 2025, after U.S. market close [1] - A live conference call and webcast will follow the financial results announcement at 4:30 p.m. ET [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3] - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Insights - Pacira BioSciences, Inc. announced updated three-year results for PCRX-201, a gene therapy for knee osteoarthritis, showing sustained clinical improvements in pain, stiffness, and function for up to 156 weeks following a single injection [1][12][8] Study Details - The open-label Phase 1 trial involved 72 patients aged 30 to 80 with moderate to severe knee osteoarthritis, assessing safety and efficacy of PCRX-201 at three different doses over 156 weeks [4][6] - Patients were evaluated using the WOMAC-A pain score, WOMAC-B stiffness score, and KOOS for function [4] Key Findings - PCRX-201 demonstrated sustained, clinically meaningful reductions in pain and stiffness, and improvements in function across all doses for three years [6][7] - The treatment had an acceptable safety profile with no serious treatment-related adverse events reported [6][7] - In the corticosteroid pretreated cohort, patients with K/L grade 2 osteoarthritis showed greater pain reduction compared to those with advanced grades [6] - Pre-existing neutralizing antibodies did not affect the treatment's effectiveness [6][7] Regulatory Designations - PCRX-201 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency, marking it as the first gene therapy candidate in osteoarthritis to achieve these designations [8][9][12] Future Developments - A Phase 2 study (ASCEND) of PCRX-201 is currently underway, focusing on a lower dose with corticosteroid pretreatment [10][12] - The innovative high-capacity adenovirus vector platform used in PCRX-201 allows for efficient gene delivery and potential for redosing [14]

Core Viewpoint - Pacira BioSciences, Inc. has received a Paragraph IV Certification Notice Letter from Qilu Pharmaceutical, indicating Qilu's intent to file a generic version of EXPAREL, which may challenge Pacira's patent rights [1][2]. Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5]. - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications, utilizing a unique multivesicular liposome technology [6]. Patent and Legal Context - Qilu Pharmaceutical claims that 18 patents related to EXPAREL are invalid or unenforceable, which could allow them to market a generic version [2]. - The contested patents belong to two families, with expiration dates in 2041 and 2044 [3]. - Pacira has 45 days to respond to the PIV Notice and may file a lawsuit to protect its intellectual property, which would trigger a 30-month stay on FDA approval for Qilu's ANDA submission [4].

Core Insights - Pacira BioSciences, Inc. is presenting real-world evidence on the clinical effectiveness and economic benefits of EXPAREL at the AMCP Nexus 2025 Annual Meeting [1][3] - The company aims to advance understanding of postsurgical pain management and reduce reliance on opioids through multimodal pain pathways [3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [5][6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [5] Research Presentations - The AMCP Nexus 2025 will feature presentations on the impact of liposomal bupivacaine on healthcare resource utilization and costs in total knee arthroplasty [4] - Additional presentations will cover outcomes related to intraoperative liposomal bupivacaine and its effects on opioid use and functional outcomes [7] Product Details - EXPAREL utilizes multivesicular liposome technology to deliver bupivacaine over time, achieving significant reductions in cumulative pain scores and opioid consumption [8] - The product is indicated for postsurgical local and regional analgesia in patients aged 6 years and older [6]

Core Viewpoint - Pacira BioSciences, Inc. has received a Paragraph IV Certification Notice Letter from The WhiteOak Group, which has filed an Abbreviated New Drug Application for a generic version of EXPAREL, claiming that the patents are invalid or not infringed [1][2] Patent and Legal Context - WhiteOak alleges that 19 patents related to EXPAREL are invalid, unenforceable, or will not be infringed by their product [2] - The contested patents are from two families, with expiration dates of January 22, 2041, and July 2, 2044 [3] - Pacira has 45 days to file a lawsuit to protect its intellectual property rights, which would trigger a 30-month stay of FDA approval for WhiteOak's ANDA submission [4] Company Overview - Pacira specializes in non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera° [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications, significantly reducing opioid consumption by up to 78% [6]